about
Cross Talk between Wnt/β-Catenin and CIP2A/Plk1 Signaling in Prostate Cancer: Promising Therapeutic ImplicationsSynergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur in vitro and in vivo and proceed through multiple mechanismsManagement of cutaneous T cell lymphoma: new and emerging targets and treatment options.The clinical and prognostic value of polo-like kinase 1 in lung squamous cell carcinoma patients: immunohistochemical analysis.Polo-like kinase 1 as target for cancer therapy.Evaluation of Polo-like kinase 1 as a potential therapeutic target in Merkel cell carcinoma.
P2860
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Polo-like kinase 1 (Plk1) in cutaneous T-cell lymphoma.
@en
type
label
Polo-like kinase 1 (Plk1) in cutaneous T-cell lymphoma.
@en
prefLabel
Polo-like kinase 1 (Plk1) in cutaneous T-cell lymphoma.
@en
P2093
P2860
P1476
Polo-like kinase 1 (Plk1) in cutaneous T-cell lymphoma.
@en
P2093
P2860
P304
P356
10.1111/J.1365-2133.2010.10128.X
P407
P577
2011-01-28T00:00:00Z